Daiichi Sankyo, AstraZeneca's highly touted ADC Datroway off to 'smooth market launch'
As the second antibody-drug conjugate launched by Daiichi Sankyo and AstraZeneca, Datroway has a tough act to follow, coming on the heels of the companies’ emerging ADC cancer powerhouse Enhertu. But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO Hiroyuki Okuzawa.
As the second antibody-drug conjugate launched by Daiichi Sankyo and AstraZeneca, Datroway has a tough act to follow, coming on the heels of the companies’ emerging ADC cancer powerhouse Enhertu. But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO Hiroyuki Okuzawa.
